Gionata Fiorino to Infliximab
This is a "connection" page, showing publications Gionata Fiorino has written about Infliximab.
Connection Strength
1.241
-
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):601-606.
Score: 0.513
-
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. Curr Med Chem. 2019; 26(2):280-287.
Score: 0.136
-
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Dig Liver Dis. 2019 04; 51(4):510-515.
Score: 0.135
-
The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018 11; 48(9):941-950.
Score: 0.133
-
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017 02; 23(2):233-243.
Score: 0.119
-
The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. Curr Pharm Des. 2017; 23(44):6759-6769.
Score: 0.119
-
Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? Dig Dis Sci. 2017 11; 62(11):2964-2965.
Score: 0.031
-
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. Dig Liver Dis. 2017 Aug; 49(8):872-877.
Score: 0.030
-
Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014 Nov; 8(11):1548-50.
Score: 0.025